公司資料
Aurinia Pharmaceuticals Inc 股價、新聞與催化劑
- 股票代碼:
- AUPH
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Canada
股票表現
15.95 USD (-1.51%)
收盤價
最後更新: 2026年10月1日
1.98B USD
市值
股價為何變動
截至 2026年10月1日，AUPH 下跌 1.51%，收於 $15.95。目前新聞監測窗口內未發現新的同公司新聞。
公司概覽
業務概覽
Aurinia Pharmaceuticals is a biopharmaceutical company focused on autoimmune disease, especially kidney-related immune disorders. Its story combines commercial products with the challenge of maintaining growth in a specialty immunology market.
所在地與產業分類
Aurinia is headquartered in Canada and listed on NASDAQ. It sits in specialty biopharma with immunology and renal exposure.
商業模式特徵
The company depends on product sales, market access, and the ability to manage a focused franchise in autoimmune disease. Investors watch revenue, label strategy, and pipeline or portfolio updates.
生技產業定位
Aurinia occupies a durable specialty-immunology niche within biotech. It has commercial grounding, but the stock remains sensitive to execution and franchise durability.
未來催化劑
- Aurinia’s catalysts are Lupkynis execution, lupus-nephritis adoption, and any label or commercial update that broadens the franchise. The market will care about whether growth stays steady.
近期新聞
新聞標題由機器翻譯，詳情為英文原文。
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。